Cellebrite DI Ltd. (NASDAQ: CLBT) reported fourth‑quarter 2025 revenue of $128.8 million, an 18% year‑over‑year increase, and full‑year revenue of $475.7 million, up 19% from $401.2 million in 2024. Net income rose to $21.3 million, while non‑GAAP net income reached $36.7 million and adjusted EBITDA climbed to $38.3 million, giving the company a 29.8% margin for the year. The company’s diluted earnings per share of $0.14 beat consensus estimates of $0.11, a $0.03 or 27% surprise, driven by disciplined cost management and a favorable mix shift toward higher‑margin SaaS and cloud offerings.
The revenue growth was largely powered by the company’s platform transformation. Inseyets, the company’s cloud‑enabled digital forensics platform, now accounts for 55% of the installed base, up from 47% at the end of 2024, reflecting strong adoption among law‑enforcement and intelligence customers. Cloud‑enabled offerings now represent 22% of total ARR, a jump from 14% at the end of 2025, and contributed $104 million of the $480.8 million ARR, up 21% from $397.8 million in 2024. The higher mix of subscription‑based revenue, combined with pricing power in the Inseyets suite, offset the modest decline in legacy on‑premise sales and helped lift top‑line growth.
Margin expansion was a key theme. Adjusted EBITDA margin grew to 29.8% from 27.5% in 2024, driven by a 4‑percentage‑point lift in gross margin to 85% and a 2‑percentage‑point improvement in operating leverage as the company scales its cloud infrastructure. The company also reported a non‑GAAP gross margin of 86% in Q4, up from 84% in Q4 2024, reflecting successful pricing of new AI‑powered modules and reduced support costs per user. These gains were partially offset by a one‑time restructuring charge of $1.2 million, but the overall margin improvement signals strong execution.
Management guided for Q1 2026 revenue of $126–$128 million, above the consensus of $125.2 million, and full‑year 2026 revenue of $565–$571 million, up from the prior guidance of $554.5 million. The company also reiterated its free‑cash‑flow margin target of 30%+ for 2026, a slight lift from the 29% target set in 2025. These upward revisions reflect confidence in continued demand for Inseyets and the expanding AI and drone‑forensics capabilities acquired through the Corellium deal. The guidance also signals that the company expects to maintain its cost discipline while investing in high‑return verticals.
Headwinds remain, notably the challenging U.S. federal spending environment, which could dampen demand from government agencies. Nevertheless, the company’s strategic focus on AI, cloud, and drone‑forensics, coupled with the Corellium acquisition, positions it to capture new market segments. CEO Thomas E. Hogan noted, “Despite a challenging U.S. Federal spending environment, we drove 21% ARR growth in 2025, reflecting expansion across all major geographies and flagship offerings.” CFO David Barter added, “We remain well positioned to scale efficiently and reaccelerate ARR growth in 2026, while maintaining strong operating profitability.”
Market reaction to the results was mixed. While the earnings beat and revenue beat were clear, investors weighed the modest margin lift against the company’s high valuation and the ongoing federal budget uncertainty. The stock’s pre‑market decline and subsequent extended‑trading gains illustrate that the market is cautiously optimistic, recognizing the company’s solid fundamentals but remaining wary of potential headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.